These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 8682124)

  • 1. Paradoxical acute brain thromboembolism during prostacyclin (PGI2) acute challenge for primary pulmonary hypertension.
    Raffy O; Sleiman C; Mal H; Fournier M; Pariente R
    Eur Heart J; 1996 Jan; 17(1):153-4. PubMed ID: 8682124
    [No Abstract]   [Full Text] [Related]  

  • 2. Paradoxical acute thromboembolism during prostacyclin administration.
    Kritz H; Sinzinger H
    Eur Heart J; 1997 Oct; 18(10):1679. PubMed ID: 9347283
    [No Abstract]   [Full Text] [Related]  

  • 3. Beneficial hemodynamic effects of oral prostacyclin (PGI2) analogue, beraprost sodium, on a patient with primary pulmonary hypertension--a case report.
    Hashida H; Hamada M; Shigematsu Y; Ikeda S; Kuwahara T; Kawakami H; Hara Y; Kodama K; Kohara K; Hiwada K
    Angiology; 1998 Feb; 49(2):161-4. PubMed ID: 9482517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol.
    Frost AE; Quiñones MA; Zoghbi WA; Noon GP
    J Heart Lung Transplant; 2005 Apr; 24(4):501-3. PubMed ID: 15797757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary Hypertension and Atrial Septal Defect: Management Dilemma.
    El-Kersh K; Howsare M; Zaidi A; Flaherty MP; Smith JS
    Am J Ther; 2017; 24(5):e602-e605. PubMed ID: 27574933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost.
    Higenbottam TW; Butt AY; Dinh-Xaun AT; Takao M; Cremona G; Akamine S
    Heart; 1998 Feb; 79(2):175-9. PubMed ID: 9538312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of acute vasoresponsiveness in patients with pulmonary hypertension: treatment implications.
    Arunthari V; Heckman MG; Burger CD
    South Med J; 2010 Jul; 103(7):630-4. PubMed ID: 20531064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapy of severe pulmonary hypertension with prostacyclin and iloprost].
    Matthes J; Mathen F; Herzig S; Wassermann K
    Dtsch Med Wochenschr; 2001 May; 126(21):631-7. PubMed ID: 11413752
    [No Abstract]   [Full Text] [Related]  

  • 9. [Pulmonary embolism and paradoxical embolism in a patient with chronic respiratory insufficiency treated with mechanical ventilation].
    Abroug F; Ayari M; Belghith M; Boudjaria R; Bouchoucha S
    Rev Pneumol Clin; 1990; 46(1):39-42. PubMed ID: 2371479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prostacyclin and iloprost in aerosol form in severe pulmonary hypertension].
    Olschewski H; Walmrath D; Schermuly R; Ghofrani HA; Grimminger F; Seeger W
    Pneumologie; 1998 Jan; 52(1):3-7. PubMed ID: 9540363
    [No Abstract]   [Full Text] [Related]  

  • 11. [How to do vasoreactivity test?].
    Canpolat U; Kaya EB
    Turk Kardiyol Dern Ars; 2012 Jun; 40(4):386-9. PubMed ID: 22951858
    [No Abstract]   [Full Text] [Related]  

  • 12. Sudden death during a change in treatment for pulmonary hypertension.
    Brun H; Holmström H; Thaulow E
    Cardiol Young; 2005 Apr; 15(2):223-5. PubMed ID: 15845169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined ostium secundum type ASD and pulmonary arterial thromboembolism causing pulmonary artery enlargement, pulmonary hypertension and recurrent paradoxical cerebral embolism due to deep venous thrombosis.
    Funabashi N; Takaoka H; Ozawa K; Tanabe N; Tatsumi K; Saeki N; Higashide T; Uno T; Kobayashi Y
    Int J Cardiol; 2016 Mar; 207():303-7. PubMed ID: 26814633
    [No Abstract]   [Full Text] [Related]  

  • 14. Atrial septal defect closure in a patient with "irreversible" pulmonary hypertensive arteriopathy.
    Schwerzmann M; Zafar M; McLaughlin PR; Chamberlain DW; Webb G; Granton J
    Int J Cardiol; 2006 Jun; 110(1):104-7. PubMed ID: 15992947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epoprostenol for primary pulmonary hypertension.
    Med Lett Drugs Ther; 1996 Feb; 38(968):14-5. PubMed ID: 8592477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapy is required for management of pulmonary arterial hypertension after defect closure in adult patients with atrial septal defect and associated pulmonary arterial hypertension.
    Fujino T; Yao A; Hatano M; Inaba T; Muraoka H; Minatsuki S; Imamura T; Maki H; Kinugawa K; Ono M; Nagai R; Komuro I
    Int Heart J; 2015; 56(1):86-93. PubMed ID: 25742945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dilated conjunctival vessels in a patient undergoing epoprostenol therapy.
    Foroozan R; Chan-Kai B; Marx DP
    Clin Exp Ophthalmol; 2007 Dec; 35(9):877-8. PubMed ID: 18173425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcatheter closure of atrial septal defect protects from pulmonary edema: septal occluder device gradually reduces LR shunt.
    Murakami T; Nakazawa G; Horinouchi H; Torii S; Ijichi T; Ohno Y; Amino M; Shinozaki N; Ogata N; Yoshimachi F; Yoshioka K; Ikari Y
    Heart Vessels; 2017 Jan; 32(1):101-104. PubMed ID: 27314266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhaled prostacyclin following surgical repair of congenital heart disease--a pilot study.
    Carroll CL; Backer CL; Mavroudis C; Cook K; Goodman DM
    J Card Surg; 2005; 20(5):436-9. PubMed ID: 16153274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Congenital right pulmonary artery agenesis with atrial septal defect and pulmonary hypertension.
    Orun UA; Yilmaz O; Bilici M; Karademir S; Uner C; Senocak F; Dogan V
    Congenit Heart Dis; 2012; 7(3):E6-9. PubMed ID: 21801314
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.